阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3210人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048049, encodeId=2d3f204804982, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, objectType=article, longId=195026, objectId=3746195026a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3746195026a6, replyNumber=0, likeNumber=73, createdTime=2020-11-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3746195026a6, moduleTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3746195026a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048037, encodeId=51ae204803e68, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：派姆单抗联合新辅助化疗治疗早期三阴性乳腺癌, objectType=article, longId=188999, objectId=ac0d18899920, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0d18899920, replyNumber=0, likeNumber=77, createdTime=2020-03-05, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0d18899920, moduleTitle=NEJM：派姆单抗联合新辅助化疗治疗早期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0d18899920)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048040, encodeId=3bb7204804040, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, objectType=article, longId=192310, objectId=61191923102d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61191923102d, replyNumber=0, likeNumber=73, createdTime=2020-06-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61191923102d, moduleTitle=转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61191923102d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048034, encodeId=5e6d204803459, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Dis：TLR5可作为三阴性乳腺癌的预后及监测标志物, objectType=article, longId=187135, objectId=4b5718e1350f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b5718e1350f, replyNumber=0, likeNumber=89, createdTime=2020-05-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b5718e1350f, moduleTitle=Cell Death Dis：TLR5可作为三阴性乳腺癌的预后及监测标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b5718e1350f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048042, encodeId=c7402048042cc, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nat Cell Biol：三阴性乳腺癌需要对“症”下药, objectType=article, longId=193017, objectId=364f19301e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=364f19301e13, replyNumber=0, likeNumber=55, createdTime=2021-03-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=364f19301e13, moduleTitle=Nat Cell Biol：三阴性乳腺癌需要对“症”下药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=364f19301e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048048, encodeId=f41c204804809, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, objectType=article, longId=194629, objectId=5ba51946297d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba51946297d, replyNumber=0, likeNumber=115, createdTime=2021-01-18, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba51946297d, moduleTitle=靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba51946297d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048047, encodeId=c5c5204804ee4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, objectType=article, longId=194614, objectId=d3b0194614fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b0194614fc, replyNumber=0, likeNumber=76, createdTime=2020-08-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b0194614fc, moduleTitle=英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b0194614fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048024, encodeId=95b12048024b3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=2019BOC/BOA︱郝春芳教授：IMpassion 130研究落地开花，三阴性乳腺癌免疫治疗证据确立, objectType=article, longId=175204, objectId=ac221e52049a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac221e52049a, replyNumber=0, likeNumber=68, createdTime=2019-08-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac221e52049a, moduleTitle=2019BOC/BOA︱郝春芳教授：IMpassion 130研究落地开花，三阴性乳腺癌免疫治疗证据确立, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac221e52049a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048028, encodeId=dc9c2048028ff, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌患者的同情治疗：Leronlimab获得了IRB的批准, objectType=article, longId=182988, objectId=480e18298806, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480e18298806, replyNumber=0, likeNumber=64, createdTime=2020-10-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480e18298806, moduleTitle=三阴性乳腺癌患者的同情治疗：Leronlimab获得了IRB的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480e18298806)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048038, encodeId=9b6a204803859, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=沈朋教授专访：特殊疫情之下，共话三阴性乳腺癌研究, objectType=article, longId=191997, objectId=6e8719199eb2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e8719199eb2, replyNumber=0, likeNumber=82, createdTime=2020-07-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e8719199eb2, moduleTitle=沈朋教授专访：特殊疫情之下，共话三阴性乳腺癌研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e8719199eb2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048036, encodeId=077f2048036f9, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PNAS：三阴性乳腺癌靶向治疗新突破：mRNA编辑是关键！, objectType=article, longId=188264, objectId=c10d1882640b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c10d1882640b, replyNumber=0, likeNumber=128, createdTime=2020-10-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c10d1882640b, moduleTitle=PNAS：三阴性乳腺癌靶向治疗新突破：mRNA编辑是关键！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c10d1882640b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048018, encodeId=75f72048018ae, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌耐药是可逆的！靶向药物正在临床试验中, objectType=article, longId=165735, objectId=c179165e35b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c179165e35b0, replyNumber=0, likeNumber=57, createdTime=2019-10-05, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c179165e35b0, moduleTitle=三阴性乳腺癌耐药是可逆的！靶向药物正在临床试验中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c179165e35b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048020, encodeId=6a2520480201f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=BMC Cancer：基于三阴性乳腺癌新患者来源异种移植模型的耐药分析, objectType=article, longId=168682, objectId=70fc16868291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70fc16868291, replyNumber=0, likeNumber=60, createdTime=2019-08-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70fc16868291, moduleTitle=BMC Cancer：基于三阴性乳腺癌新患者来源异种移植模型的耐药分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70fc16868291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048019, encodeId=5da920480191a, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌的免疫治疗, objectType=article, longId=168208, objectId=8aa9168208c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aa9168208c8, replyNumber=0, likeNumber=61, createdTime=2019-12-14, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aa9168208c8, moduleTitle=三阴性乳腺癌的免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8aa9168208c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048030, encodeId=1972204803052, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PNAS发文揭示治疗多发性骨髓瘤和三阴性乳腺癌的潜在药物靶点和候选药物分子, objectType=article, longId=184311, objectId=02b2184311ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02b2184311ca, replyNumber=0, likeNumber=0, createdTime=2020-03-27, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02b2184311ca, moduleTitle=PNAS发文揭示治疗多发性骨髓瘤和三阴性乳腺癌的潜在药物靶点和候选药物分子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02b2184311ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048027, encodeId=a588204802eb8, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Lancet Oncol：Trilaciclib三联化疗方案治疗三阴性乳腺癌, objectType=article, longId=180289, objectId=4b3918028931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b3918028931, replyNumber=0, likeNumber=59, createdTime=2020-01-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b3918028931, moduleTitle=Lancet Oncol：Trilaciclib三联化疗方案治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b3918028931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048026, encodeId=95c12048026f2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, objectType=article, longId=178551, objectId=036a1e8551e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=036a1e8551e1, replyNumber=0, likeNumber=49, createdTime=2020-07-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=036a1e8551e1, moduleTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=036a1e8551e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048023, encodeId=63a520480238e, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗, objectType=article, longId=174828, objectId=f9cd1e48285c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9cd1e48285c, replyNumber=0, likeNumber=92, createdTime=2020-05-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9cd1e48285c, moduleTitle=三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9cd1e48285c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048006, encodeId=00ed204800660, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CLIN CANCER RES：细胞外HMGA1促进三阴性乳腺癌侵袭与转移, objectType=article, longId=156444, objectId=5c7a1564449f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7a1564449f, replyNumber=0, likeNumber=80, createdTime=2019-01-01, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7a1564449f, moduleTitle=CLIN CANCER RES：细胞外HMGA1促进三阴性乳腺癌侵袭与转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c7a1564449f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048022, encodeId=02cd20480226f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Carcinogenesis：连难搞的三阴性乳腺癌，这个降糖药也能神助攻, objectType=article, longId=174635, objectId=863e1e4635b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=863e1e4635b7, replyNumber=0, likeNumber=69, createdTime=2019-09-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=863e1e4635b7, moduleTitle=Carcinogenesis：连难搞的三阴性乳腺癌，这个降糖药也能神助攻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=863e1e4635b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）

2020-11-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：派姆单抗联合新辅助化疗治疗早期三阴性乳腺癌

2020-03-05

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

转移性三阴性乳腺癌治疗获突破：性抗体偶联疗法疗效显著

2020-06-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Dis：TLR5可作为三阴性乳腺癌的预后及监测标志物

2020-05-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nat Cell Biol：三阴性乳腺癌需要对“症”下药

2021-03-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

靶向Trop-2用于三阴性乳腺癌重磅ADC药物在中国启动II期临床

2021-01-18

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

英国NICE批准罗氏的PD-L1单抗Tecentriq，用于治疗三阴性乳腺癌

2020-08-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

2019BOC/BOA︱郝春芳教授：IMpassion 130研究落地开花，三阴性乳腺癌免疫治疗证据确立

2019-08-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌患者的同情治疗：Leronlimab获得了IRB的批准

2020-10-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

沈朋教授专访：特殊疫情之下，共话三阴性乳腺癌研究

2020-07-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PNAS：三阴性乳腺癌靶向治疗新突破：mRNA编辑是关键！

2020-10-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌耐药是可逆的！靶向药物正在临床试验中

2019-10-05

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

BMC Cancer：基于三阴性乳腺癌新患者来源异种移植模型的耐药分析

2019-08-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌的免疫治疗

2019-12-14

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PNAS发文揭示治疗多发性骨髓瘤和三阴性乳腺癌的潜在药物靶点和候选药物分子

2020-03-27

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Lancet Oncol：Trilaciclib三联化疗方案治疗三阴性乳腺癌

2020-01-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

2020-07-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌：BRCA检测推动三阴性乳腺癌的精准治疗

2020-05-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CLIN CANCER RES：细胞外HMGA1促进三阴性乳腺癌侵袭与转移

2019-01-01

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Carcinogenesis：连难搞的三阴性乳腺癌，这个降糖药也能神助攻

2019-09-30

科室
- - 订阅+
  - 更多科室
工具
服务